Brian L. Clevinger
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian L. Clevinger.
Biochemical and Biophysical Research Communications | 1983
Horace M. Perry; Jean Chappel; Brian L. Clevinger; John G. Haddad; Steven L. Teitelbaum
We have developed a monoclonal antibody capable of detecting 1 pg/ml of 1,25-dihydroxycholecalciferol. At a dilution of 1:80,000 of ascitic fluid this antibody has an apparent KD of 3.3 X 10(-11) ML-1. The immunogen used was a vitamin D analogue, calcitroic acid [1 alpha, 3 beta-dihydroxy-9, 10 seco-24-nor 5, 7, 10 (19) cholatriene-23-oic acid], conjugated to bovine serum albumin. Although this antibody is extremely sensitive, it also recognizes other important vitamin D3 metabolites.
Archive | 1980
Brian L. Clevinger; James W. Schilling; Rogers C. Griffith; Daniel Hansburg; Leroy Hood; Joseph M. Davie
Idiotypic (variable-region) antigenic determinants have been extremely important to the study of immunoglobulins. These antigenic determinants have been widely used to examine variable-region expression in immunoglobulin populations because they offer a simple, sensitive, serological approach to variable-region structure. There are many different categories of idiotypic determinants: ligand-modifiable (binding site determinants), ligand-nonmodifiable (framework determinants), VL-specific, VH-specific, and those requiring both VL and VH. In addition, determinants shared by variable regions known to be structurally different are called IdX, cross-reactive, or public idiotypes, while those apparently restricted to identical variable regions are IdI, individual, or private idiotypes.
Molecular Immunology | 1986
Michael V. Seiden; A. Srouji; Brian L. Clevinger; Joseph M. Davie
In order to more accurately determine the distribution of antigenic determinants detected by antisera to hypervariable-region and JH1 peptides, we measured the frequency of lymphocytes stained with these sera by flow cytometry. None of the sera specific for HV1, HV2 or HV3 peptides stained significant numbers of lymphocytes, but those specific for JH1 reacted with nearly all B-cells.
Journal of Experimental Medicine | 1980
Brian L. Clevinger; Jim Schilling; Leroy Hood; Joseph M. Davie
Annual Review of Immunology | 1986
Joseph M. Davie; Michael V. Seiden; Neil S. Greenspan; Charles T. Lutz; Timothy Bartholow; Brian L. Clevinger
Arthritis & Rheumatism | 1980
Bevra H. Hahn; Fanny M. Ebling; Sandra K. Freeman; Brian L. Clevinger; Joseph M. Davie
Journal of Experimental Medicine | 1983
Barbara Newman; Shunji Sugii; Elvin A. Kabat; Mitsuo Torii; Brian L. Clevinger; Jim Schilling; Martha W. Bond; Joseph M. Davie; Leroy Hood
Archive | 1983
Brian L. Clevinger; John G. Haddad; Steven L. Teitelbaum
Journal of Experimental Medicine | 1984
M.V. Seiden; Brian L. Clevinger; S. McMillan; A Srouji; Richard A. Lerner; Joseph M. Davie
Molecular Immunology | 1986
Barbara A. Newman; Jerry Liao; Flavio Gruezo; Shunji Sugii; Elvin A. Kabat; Mitsuo Torii; Brian L. Clevinger; Joseph M. Davie; Jim Schilling; Martha W. Bond; Leroy Hood